Clinical trials
Urinary Bladder Neoplasms trials in South Korea
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
94 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2005 | 1 |
| 2007 | 2 |
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 2 |
| 2012 | 1 |
| 2013 | 2 |
| 2014 | 4 |
| 2015 | 4 |
| 2016 | 5 |
| 2017 | 5 |
| 2018 | 10 |
| 2019 | 8 |
| 2020 | 9 |
| 2021 | 10 |
| 2022 | 7 |
| 2023 | 6 |
| 2024 | 7 |
| 2025 | 5 |
| 2026 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 42 |
| Recruiting | 20 |
| Active, not recruiting | 18 |
| Terminated | 7 |
| Unknown status | 6 |
| Not yet recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Asan Medical Center | 8 |
| Merck Sharp & Dohme LLC | 7 |
| Seoul National University Hospital | 7 |
| AstraZeneca | 6 |
| Janssen Research & Development, LLC | 5 |
| Yonsei University | 5 |
| Eli Lilly and Company | 4 |
| Pfizer | 4 |
| Bayer | 3 |
| Bristol-Myers Squibb | 3 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Urinary Bladder Neoplasms | 94 |
| Carcinoma, Transitional Cell | 20 |
| Ovarian Neoplasms | 13 |
| Carcinoma, Non-Small-Cell Lung | 10 |
| Prostatic Neoplasms | 10 |
| Ureteral Neoplasms | 10 |
| Colorectal Neoplasms | 9 |
| Pancreatic Neoplasms | 9 |
| Esophageal Neoplasms | 8 |
| Lung Neoplasms | 8 |
Trials
Showing 1 to 25 of 94. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.